Clinical Trials Browser

Phase 2 × sacituzumab govitecan × Gastrointestinal × Clear all

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06329869 2024-12-02

SG-ESCC

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma